删除或更新信息,请邮件至freekaoyan#163.com(#换成@)

中国科学院上海药物研究所导师教师师资介绍简介-王春河

本站小编 Free考研考试/2021-02-10

xm:王春河
xb:男
zc:研究员
xl:博士
dh:
cz:
dzyj:wangc@simm.ac.cn
grzy:
zjlb:研究员
zw:课题组长
txdz:上海市蔡伦路720弄张江药谷1号楼342室
grjj:1999年博士毕业于中科院上海药物研究所,在美国俄勒冈健康科学大学任博士后及助理教授期间,曾经研发出治疗多发性硬化症的融合蛋白药物,并在美国完成I期临床。2009年加入的美国礼来公司的生物技术药物发现研究部,专业从事抗体药物的筛选和表征工作,是礼来上市药物白介素17抗体的研发团队成员。2015年回国共建中科院上海药物研究所生物技术药物研发中心,负责抗体药物的前期研发工作。现承担国家新药创制重大专项、中科院重大科技先导专项及国家自然科学基金等新药研发及基础研究项目。2015入选科技部“双创人才”。

教育经历:  

1.1999.04-2005.03,美国俄勒冈健康科学大学,免疫学博士后

2.1994.08-1999.06,中国科学院上海药物研究所,药理学博士

3.1990.09-1994.06,山东大学,微生物学系,理学学士


yjfx:1. 单克隆及双特异性抗体药物分子的发现、筛选和工程技术改造;

2. 新型抗体化学药物偶联体(ADC)药物的连接子改造;

3. “通用型”新冠病毒抗体研发。


dblz:1.王春河、万亚坤、黄鹏、李佳。生物技术药物兴起与展望。《现代药物研发回顾与展望--新药研发何去何从》,白东鲁、沈竞康编,化工出版社。

2. Shao, T., Chen T., Chen, Y., Liu, X., Chen, Y.L., Wang, Q., Wang C., 2020. Construction of Paclitaxel-Based Antibody Drug Conjugate with PEGylated Linker to Achieve Superior Therapeutic Index. Signal Transduction and Targeted Therapy. 15:132.

3. Bodhankar, S., Wang, C., Vandenbark, A.A., and Offner, H. 2011. Estrogen-induced protection against experimental autoimmune encephalomyelitis is abrogated in the absence of B cells. Eur. J. Immunol. 41:1165.

4.Wang, C., Li, Y., Proctor, T. M., Vandenbark, A. A. and Offner H. 2010. Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. J. Neurosci. Res. 88:7.

5.Wang, C., Dehghani, B., Li, Y., Kaler, L. J., Vandenbark, A. A., and Offner H., 2009. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 126:329.

6.Wang, C., Dehghani, B., Li, Y., Kaler, L. J., Proctor, T., Vandenbark, A. A. and Offner, H. 2009. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J. Immunol. 182:3294.

7. Offner, H., Sinha, S., Wang, C., Burrows, G. G., and Vandenbark. A. A., 2008. Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis. Rev. Neurosci. 19:327.

8.Wang, C., Dehghani, B., Magrisso, I. J., Rick, E. A., Bonhomme, E., Cody, D. B., Elenich, L. A., Subramanian, S., Murphy, S. J., Kelly, M. J., Rosenbaum, J. S., Vandenbark, A. A. and Offner H. 2008. GPR30 contributes to estrogen-induced thymic atrophy. Mol. Endocrinol. 22:636.

9.Wang, C., Gold, B.G., Kaler, L.J., Yu, X., Afentoulis, M.E., Burrows G.G., Vandenbark, A.A., Bourdette, D.N., Offner, H. 2006. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J. Neurochem. 98: 1816.

10.Wang, C., Chou, Y. C., Rich, C. M., Link, J.M., Afentoulisa, M. E., van Noort, J. M., Wawrousekd, E. F., Offner, H., Vandenbarka, A. A. 2006. αB-crystallin-reactive T cells from knockout mice are not encephalitogenic. J. Neruoimmunol. 176: 51.

11. Offner, H., Subramanian, S., Parker, S.M., Wang, C., Afentoulis, M. E., Lewis, A., Vandenbark, A. A. and Hurn P. D. 2006. Splenic atrophy in experimental stroke is accompanied by increased Treg cells and circulating macrophages. J. Immunol. 176: 6523.

12. Offner, H., Subramanian, S., Wang, C., Afentoulis, M. E., Vandenbark, A. A., Huan, J., and Burrows, G. G. 2005. Treatment of passive EAE in SJL mice with a recombinant TCR ligand induces high levels of IL-13. J.Immunol. 175: 4103.

13.Wang, C., Buck, D. C., Yang, R, Macey, T. A., and Neve, K. A. 2005. Dopamine D2 receptor stimulation of mitogen-activated protein kinases mediated by cell type-dependent transactivation of receptor tyrosine kinases. J.Neurochem. 93: 899.

14. Chou, Y. K., Burrows, G. G., LaTocha, D., Wang, C., Subramanian, S., Bourdette, D. N., and Vandenbark, A. A. 2004. CD4 T-cell epitopes of human alpha B-crystallin. J.Neurosci.Res. 75: 516.

15. Wang, C., Mooney, J. L., Meza-Romero, R., Chou, Y. K., Huan, J., Vandenbark, A. A., Offner, H., and Burrows, G. G. 2003. Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation. J.Immunol. 171: 1934.

16. Vandenbark, A. A., Rich, C., Mooney, J., Zamora, A., Wang, C., Huan, J., Fugger, L., Offner, H., Jones, R., and Burrows, G. G. 2003. Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35-55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice. J.Immunol. 171: 127.

17. Burrows G. G., Chou Y. K., Wang C., Chang J. W., Finn T. P., Culbertson N. E., Kim J, Bourdette D. N., Lewinsohn D. A., Lewinsohn D. M., Ikeda M, Yoshioka T, Allen C. N., Offner H, Vandenbark A. A. 2001. Rudimentary TCR signaling triggers default IL-10 secretion by human Th1 cells. J Immunol 167: 4386.

18.Wang C, Zhou D. H., Chen J, Chi Z. Q. 1999. Leucine-2-alanine enkephalin induced delta opioid receptors internalization expressed stably in CHO cells. Acta Pharmacol Sin. 20: 491.

19.Wang C, Zhou D. H., Chen Z. J., Wei Q, Chen J, Li G. F., Pei G, Chi Z. Q. 1998. The C-truncated delta-opioid receptor underwent agonist-dependent activation and desensitization. Biochem Biophys Res Commun 249: 321.

20.Wang C, Zhou D. H., Chen J, Li G. F., Pei G., Chi Z. Q. 1997. Binding properties of C-truncated delta opioid receptors. Acta Pharmacol Sin 18: 337.

21. Wei Q, Zhou D. H., Shen Q. X., Wang C, Pei G, Chi Z. Q. 1998. Human mu-opioid receptor overexpressed in baculovirus system and its pharmacological characterizations. Acta Pharmacol Sin 19: 218.

22. Zhu X. L., Wang C, Chen Z. J., Wu Y. L., Zhou D. H., Pei G. 1997. The carboxyl terminus mouse delta-opioid receptor is not required for agonist-dependent activation. Biochem Biophys Res Commun 232: 513.


jyjl:美国俄勒冈健康科学大学,免疫学博士后
中国科学院上海药物研究所,药理学博士山东大学,微生物学系,理学学士
gzjl:中国科学院上海药物研究所,课题组长、研究员美国礼来制药公司,生物药物发现研究中心,资深科学家美国俄勒冈健康科学大学,神经免疫,助理教授
ktxm:中科院A类项目资助,300万元,项目负责人。国家自然科学基金面上项目,54万元,项目负责人。中科院战略性先导科技专项,100万元, 子课题负责人。上海市自然科学基金,25万元,项目负责人中科院药物创新自主部署项目,100万元,项目负责人。中科院药物创新自主部署项目,50万元,项目负责人。国家新药研究重点实验室开发项目,10万元,项目负责人。上海市“扬帆计划”,20万元,项目参与人。
ryhj:1.中国科学院院长奖学金一等奖2.中国科学院地奥奖学金一等奖3.中国科学院伟华奖学金一等奖4.美国多发性硬化症学会新药研发领航员奖5.约翰. 惠特克多发性硬化症青年研究****奖6.约翰.惠特克多发性硬化症青年研究****奖
xpwj:http://sourcedb.simm.cas.cn/zw/gb2020/yjzz/202008/P.jpg
kycg:1.建立了成熟的抗体药物研发技术平台;2.布局了癌症及代谢性疾病领域的生物技术药物研发管道线;3.多个分子进入工艺研发及临床前研究阶段。
shrz:1.美国免疫学学会会员;
2.国家“十三五”新药创制重大专项生物技术药物评审专家;

3.国家“十二五”新药创制重大专项生物技术药物验收和评估专家。

相关话题/中国科学院 上海药物研究所